Ensys赢得1400万美元联邦拨款用于铅止痛疗法

2024-08-27 20:43

Nano-cap biotech Ensysce Biosciences (NASDAQ:ENSC) surged ~62% in the premarket trading on Tuesday after receiving a $14M grant from the U.S. government to support investigations into its lead pain therapy candidate PF614-MPAR.
The funding issued by the National Institutes of Health (NIH) and the National Institute on Drug Abuse (NIDA) will be available over approximately three years, allowing the company to complete a Phase 1b trial for PF614-MPAR. Ensysce (ENSC) said.
Named PF614-MPAR-102, the trial builds on data from the company’s initial Phase 1 trial, PF614-MPAR-101, for the drug.
Both PF614-MPAR-102 and PF614-MPAR-101 are expected to help the company introduce PF614-MPAR as the first opioid therapy with oral overdose protection, Ensysce (ENSC) said.
The latest funding adds to $26M in federal grants allocated to the company for its Multi-Pill Abuse Resistance (MPAR) platform and its opioid use disorder (OUD) programs.

More on Ensysce Biosciences